Mesoblast (NASDAQ:MESO) Downgraded to "Hold" Rating by Jefferies Financial Group

Jefferies Financial Group cut shares of Mesoblast (NASDAQ:MESO - Free Report) from a buy rating to a hold rating in a report published on Monday morning, MarketBeat Ratings reports.

A number of other analysts also recently issued reports on MESO. Maxim Group raised Mesoblast from a "hold" rating to a "buy" rating and set a $12.00 target price on the stock in a research report on Tuesday, September 24th. StockNews.com cut Mesoblast from a "hold" rating to a "sell" rating in a research note on Wednesday, September 4th. Cantor Fitzgerald reissued an "overweight" rating on shares of Mesoblast in a research note on Thursday, August 29th. Finally, Piper Sandler upped their price target on shares of Mesoblast from $11.00 to $15.00 and gave the stock an "overweight" rating in a research report on Thursday. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, Mesoblast currently has a consensus rating of "Hold" and an average price target of $13.50.

Mesoblast Stock Up 17.8 %

Shares of MESO stock traded up $2.60 during trading on Monday, reaching $17.23. The company's stock had a trading volume of 1,173,776 shares, compared to its average volume of 743,142. Mesoblast has a one year low of $1.61 and a one year high of $19.15. The business has a fifty day moving average price of $10.62 and a 200-day moving average price of $8.37. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Pine Valley Investments Ltd Liability Co acquired a new stake in Mesoblast during the 2nd quarter valued at $80,000. Rathbones Group PLC bought a new position in shares of Mesoblast in the second quarter valued at about $95,000. XTX Topco Ltd acquired a new stake in shares of Mesoblast during the 2nd quarter worth about $103,000. Marshall Wace LLP bought a new stake in shares of Mesoblast during the 2nd quarter worth about $562,000. Finally, Lazari Capital Management Inc. grew its stake in Mesoblast by 6.6% in the 2nd quarter. Lazari Capital Management Inc. now owns 53,467 shares of the company's stock valued at $364,000 after buying an additional 3,300 shares during the last quarter. 1.43% of the stock is currently owned by institutional investors.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.